These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25674008)

  • 1. Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
    McDonell AL; Kiiskinen U; Zammit DC; Kotchie RW; Thuresson PO; Nicolay C; Haslam T; Bruinsma M; Janszen-Van Oosterhout AJ; Otto T
    Clinicoecon Outcomes Res; 2015; 7():95-103. PubMed ID: 25674008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.
    Hunt B; Ye Q; Valentine WJ; Ashley D
    Diabetes Ther; 2017 Feb; 8(1):129-147. PubMed ID: 28058656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M; Bouchard JR; Langer J
    Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
    Saunders WB; Nguyen H; Kalsekar I
    Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
    Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
    Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.
    Qiao Q; Ouwens MJ; Grandy S; Johnsson K; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():201-5. PubMed ID: 27418849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
    Ottney A
    Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
    Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
    Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
    Buse JB; Garber A; Rosenstock J; Schmidt WE; Brett JH; Videbæk N; Holst J; Nauck M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1695-702. PubMed ID: 21450987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.